Breaking News, Trials & Filings

Novavax, Serum Institute File for COVID-19 Vax Emergency Use with WHO

Novavax' recombinant nanoparticle protein-based COVID-19 vaccine with Matrix-M adjuvant demonstrates 100% protection against moderate and severe disease.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Novavax, Inc., a biotechnology company developing next-generation vaccines for serious infectious diseases, and partner, Serum Institute of India Pvt. Ltd. (SII), have submitted a regulatory filing to the World Health Organization (WHO) for emergency use listing (EUL) of Novavax’ recombinant nanoparticle protein-based COVID-19 vaccine candidate with Matrix-M™ adjuvant. The submission is based on the companies’ previous regulatory submission to the Drugs Controller General of India (D...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters